

Specialty Pharmacy Program

Orencia® (abatacept)

DESCRIPTION

Orencia is indicated for reducing signs and symptoms, inducing major clinical response, slowing the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis (RA). Orencia may be used as monotherapy or concomitantly with disease modifying antirheumatic drugs (DMARDs) other than tumor necrosis factor (TNF) antagonists.

Orencia is indicated for reducing signs and symptoms in pediatric patients 6 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis (JIA). Orencia may be used as monotherapy or concomitantly with methotrexate.

APPROVAL DURATION

Approval duration: lifetime

APPROVAL CRITERIA

- I. Diagnosis of Moderate to Severe Rheumatoid Arthritis and meets all of the following:
 - A. Patient is 18 years of age or older AND
 - B. Patient has had an inadequate response to one or more nonbiologic disease modifying anti-rheumatic agents (DMARDs), or such therapy is contraindicated or not tolerated:
 1. Auranofin (Ridaura)
 2. Azathioprine (Imuran)
 3. Cyclophosphamide (Cytoxan or Neosar)
 4. Cyclosporine (Neoral or Sandimmune)
 5. Gold sodium thiomalate (Myochrysine)
 6. Hydroxychloroquine (Plaquenil)
 7. Leflunomide (Arava)
 8. Methotrexate
 9. Minocycline (Minocin or Dynacin)
 10. Penicillamine (Cuprimine, Depen)
 11. Sulfasalazine (Azulfidine, Azulfidine EN-tabs)
 - C. Patient has had an inadequate response to a tumor necrosis factor blocking agent, or such therapy is contraindicated or not tolerated:
 1. Cimzia (certolizumab pegol)
 2. Enbrel (etanercept)
 3. Humira (adalimumab)
 4. Remicade (infliximab)
 5. Simponi (golimumab)
 - D. Patient will not use Orencia in combination with a tumor necrosis factor blocking agent or Kineret (anakinra).
- II. Diagnosis of moderate to severe Polyarticular Juvenile Idiopathic Arthritis (JIA) and meets all of the following:
 - A. Patient is 6 years of age or older; AND
 - B. Patient has had an inadequate response to Enbrel (etanercept) or Humira (adalimumab), or such therapy is contraindicated or not tolerated; AND
 - C. Patient will not use Orencia in combination with a tumor necrosis factor blocking agent or Kineret (anakinra).
 1. Orencia may be used as monotherapy or concomitantly with methotrexate.